IMCR(Immunocore Holdings plc) · 财务报表

IMCR(Immunocore Holdings plc) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$36.48M$174.36M$249.43M$310.20M$400.02M
毛利润$36.48M$173.27M$248.39M$307.47M$394.93M
营业利润−$174.59M−$51.71M−$59.65M−$70.46M−$45.35M
净利润−$180.03M−$52.54M−$55.29M−$51.09M−$35.51M
经营现金流−$143.11M−$49.21M$2.94M$26.06M−$10.71M
自由现金流−$144.49M−$51.41M−$2.48M$20.89M−$15.05M
摊薄每股收益$-4.24$-1.15$-1.13$-1.02$-0.71

Immunocore Holdings plc IMCR